[go: up one dir, main page]

WO2016001933A1 - Dispositif pour la préparation d'un échantillon biologique pour vitrification, et procédé d'utilisation de celui-ci - Google Patents

Dispositif pour la préparation d'un échantillon biologique pour vitrification, et procédé d'utilisation de celui-ci Download PDF

Info

Publication number
WO2016001933A1
WO2016001933A1 PCT/IL2015/050691 IL2015050691W WO2016001933A1 WO 2016001933 A1 WO2016001933 A1 WO 2016001933A1 IL 2015050691 W IL2015050691 W IL 2015050691W WO 2016001933 A1 WO2016001933 A1 WO 2016001933A1
Authority
WO
WIPO (PCT)
Prior art keywords
liquid
chamber
carrier
sample
drain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2015/050691
Other languages
English (en)
Inventor
Amir Arav
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FERTILESAFE Ltd
Original Assignee
FERTILESAFE Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FERTILESAFE Ltd filed Critical FERTILESAFE Ltd
Publication of WO2016001933A1 publication Critical patent/WO2016001933A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/14—Mechanical aspects of preservation; Apparatus or containers therefor
    • A01N1/146—Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving
    • A01N1/147—Carriers for immersion in cryogenic fluid for slow freezing or vitrification
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/14—Mechanical aspects of preservation; Apparatus or containers therefor

Definitions

  • the invention relates to the field of cryopreservation. More precisely, it relates to devices for vitrification of biological samples.
  • cryopreservation Preservation of biological samples, for example oocytes and embryos at very low temperature is known as cryopreservation.
  • One of the major challenges of cryopreservation is to prevent the intracellular liquid within the sample from turning into ice crystals.
  • Two common techniques of cryopreservation are slow freezing and vitrification.
  • vitrification may be further enabled by increasing the viscosity of the sample, for example by applying various cryoprotectants and/or other applicable additives, by reducing the volume of the sample, or by a combination thereof.
  • the publication "Vitrification of oocytes and embryos” (Amir Arav, "Embryonic development and manipulation in animal development", edited by A. Lauria and F. Gandolfi, Portland Press, London, U.K., 1992), presents a method of vitrifying cells enclosed in small drops sufficient to keep them in physiological conditions.
  • Arav reports that with volume of 70 nanoliter drops, good survival rates can be achieved even with low concentration of cryoprotectant.
  • Vitrification is further described in the following publications: "Titration of Vitrification Solution in Mouse Embryo Cryopreservation" (A. ARAV, L. GIANAROLI, AND P. SURIANO, Cryobiology 25(6), 1988) presents reducing the toxicity of the vitrification solution by decreasing the time and temperature of embryo exposure to cryoprotectant solution.
  • Embryo cryopreservation in the presence of low concentration of vitrification solution with sealed pulled straws in liquid nitrogen slush presents a vitrification method that combines LN slush and sealed pulled straws (SPS).
  • U.S. Patent Application 2011/0207112 discloses an automated system and method of cryopreservation and reanimation of oocytes, embryos, or blastocysts.
  • One or more oocytes or embryos are positioned in a processing container, the processing container being configured to allow fluid to flow into and out of the processing container, where two or more fluids flow into and out of the processing container with oocytes or embryos therein.
  • the present invention in some embodiments thereof, relates to the vitrification of a biological sample.
  • the invention relates to a device for preparing a biological sample for vitrification, the device comprising a chamber configured to contain a first liquid and to accommodate a carrier for holding the sample immersed in the first liquid; an inlet configured to add a second liquid into the chamber for modifying a composition of the first liquid; and a first drain configured to drain the first liquid from the chamber; wherein the chamber has a liquid capacity that is sufficiently large to enable a gradual modification of the composition in accordance with a modification course adequate for preparing the sample for vitrification
  • the device further comprises a first drain configured to drain the first liquid from the chamber; wherein the chamber and the first drain are configured together to induce a directional flow of the first liquid, wherein the directional flow forces the biological sample to reside substantially at a predetermined location
  • the inlet is coupleable to a manual injection pump; and the manual injection pump together with the liquid capacity enables the gradual modification of the first liquid.
  • the manual injection pump is a syringe.
  • the chamber is configured to accommodate a carrier characterized by a size adequate for placing a biological sample therewith by manual pipetting.
  • the chamber is configured to accommodate a carrier that comprises a permeable member, which is configured to enable a thru-flow of the first liquid between sides thereof, while preventing the biological sample from being carried along with the thru-flow.
  • the permeable member is located at a bottom of the carrier.
  • the first drain is configured to enable abrupt exhaustion of substantially all the first liquid from the first container.
  • the first drain is coupleable to a manual aspiration pump.
  • the first drain is configured to enable abrupt exhaustion of substantially all the first liquid from the first container.
  • the first drain is configured to enable aspiration of gas therethrough; the inlet is configured to deliver gas into the chamber; and the chamber, the inlet, and the first drain are configured so that the aspiration of gas induces a flow of gas at a vicinity of the sample, thus removing a part of a residual liquid.
  • the device further comprises a flow guiding element configured to guide a flow of the second liquid toward the carrier.
  • the flow guiding element is configured to guide the flow to an opening of the carrier.
  • the chamber is configured to accommodate a plurality of carriers.
  • the chamber comprises a liquid guiding element configured to guide a flow of the second liquid toward the plurality of carriers.
  • the device further comprises a second drain configured to enable flow of an excessive volume of the first liquid out of the chamber, wherein the excessive volume exceeds a first level limit, thus constraining the first liquid substantially below the first-liquid-limit.
  • the first-level-limit is configurable.
  • the chamber comprises a first container configured to contain the first liquid and to accommodate the carrier; and the device further comprises a second drain configured to enable flow of an excessive volume of the first liquid out of the first container, the excessive volume exceeds a first level limit, thus constraining the first liquid substantially below the first-liquid-limit.
  • the first-level-limit is configurable.
  • the device further comprises an inspection element configured to enable visual inspection of the biological sample for enabling monitoring a status thereof; and an illumination element configured to enable illuminating the sample for enabling the visual inspection.
  • the chamber is configured to accommodate the carrier so that the sample resides substantially between the illumination element and the inspection element, thus enabling trans-illumination of the sample.
  • the illumination element is located substantially below the carrier; and the inspection element is located substantially above the carrier.
  • the inspection element is an internal inspection element residing inside the chamber.
  • the internal inspection element comprises a camera. In some embodiments, the internal inspection element comprises an optic fiber.
  • the illumination element is an internal illumination element residing inside the chamber.
  • the internal illumination element comprises a Light
  • LED Emitting Diode
  • the internal illumination element comprises an optic fiber.
  • the inspection element comprises an inspection window, wherein the inspection window comprises an opening in a boundary of the chamber, and enables inspection of the sample therethrough.
  • the inspection window is configured to be closed by an inspection-window-cover comprising a transparent member, thus enabling visual inspection while maintaining the chamber closed.
  • the illumination element comprises an illumination window, wherein the illumination window comprises an opening in a boundary of the chamber, and enables illuminating the sample by light penetration therethrough.
  • the illumination window is configured to be closed by an illumination-window-cover comprising a transparent member, thus enabling illumination while maintaining the chamber closed.
  • the invention also relates to a method for vitrifying a reproductive multi cell suspension, the method comprising immersing the multi cell suspension in a carrier in a first liquid residing in a chamber, wherein the first liquid is of a first composition; gradually modifying the first liquid from the first composition to a third composition at a first modification course, which is adequate for vitrification, by adding a second liquid of a second composition; and abruptly modifying the composition of the first liquid from the third composition to a forth composition by draining substantially all of the first liquid, and adding a third liquid of a forth composition.
  • adding the second liquid is performed manually.
  • adding adding the third liquid is performed manually
  • draining liquids is performed manually.
  • the method further comprises maintaining the multi cell suspension substantially adjacent to a permeable member of the carrier by draining part of the first liquid, thus inducing a directional flow thereof through the permeable member, and thereby forcing the multi cell suspension to reside substantially adjacent to the permeable member.
  • the method further comprises placing the multi cell suspension at the carrier by manual pipetting.
  • a volume of the first liquid and a volume of the second liquid occupy together at least 1 milliliter.
  • a volume of the first liquid and a volume of the second liquid occupy together at least 5 milliliter.
  • the method further comprises immersing two or more multi cell suspensions in two or more carriers in the first liquid residing in the chamber.
  • the method further comprises constraining the first liquid substantially below a first-liquid-limit, by enabling out-flow of an excessive volume of the first liquid, the excessive volume exceeds a first level limit.
  • the method further comprises visually inspecting the multi-cell suspension residing within the chamber.
  • visually inspecting comprises trans-illuminating the multi-cell suspension.
  • the method further comprises controlling the draining part of the first liquid responsive to information obtained during the visually inspecting.
  • the method further comprises draining substantially all the first liquid; and aspiring gas, thus inducing a flow of gas at a vicinity of the multi- cell suspension, and thereby reducing a volume of a residual liquid.
  • FIG 1 illustrates a cryopreservation system for vitrification of a reproductive biological sample, according to embodiments of the invention
  • FIG 2 illustrates a cryopreservation device, according to certain embodiments of the invention
  • FIG 2A illustrates a cryopreservation device 2A02 comprising a flow guiding element 2A06, according to embodiments of the invention
  • FIG 3 illustrates a cryopreservation device 302, further comprising a first drain 306, according to embodiments of the invention
  • FIG 4 illustrates a cryopreservation device configured to enable reduction of volume of a residual liquid by aspirating gas, according to embodiments of the invention
  • FIG 5 illustrates a cryopreservation device further comprising a second drain, according to embodiments of the invention
  • FIG 5A illustrates a cryopreservation device, according to embodiments of the invention
  • FIG 6 illustrates two cryopreservation devices comprising a second container, according to embodiments of the invention.
  • FIG 7 illustrates a cryopreservation device, according to embodiments of the invention.
  • FIG 8 illustrates a cryopreservation device configured to enable visual inspection of the reproductive biological sample residing within the chamber, according to embodiments of the invention.
  • FIG 9 schematically illustrates a cryopreservation method for vitrification of a reproductive multi cell suspension, by using a cryopreservation device in accordance with embodiments of the invention.
  • FIG 1 illustrates a cryopreservation system 102 for vitrification of a biological sample 104, according to embodiments of the invention.
  • the source of the biological samples may be any animal, including but not restricted to human beings, mammals, and vertebrates.
  • the biological sample is a multi-cell suspension, for example an oocyte, an embryo, or another multi-cell suspension.
  • the biological sample is a tissue, for example a slice of an ovary tissue, etc.
  • the invention is used for handling reproductive biological samples (such as oocytes, sperm, embryos, ovary tissues etc.).
  • reproductive biological samples such as oocytes, sperm, embryos, ovary tissues etc.
  • the invention is not limited to reproductive biological samples and may be directed to other kinds of biological samples.
  • One non limiting example for using the invention with other (non- reproductive) kinds of biological samples is preparing a piece of tissue (or pieces of tissue) taken in a biopsy for vitrification, before the piece can be sent for analysis.
  • System 102 utilizes a cryopreservation device 106 which enables the preparation of a sample for vitrification. As illustrated in the present figure, preparation is initiated by placing the sample in or on a carrier 108 accommodated in device 102, so that the sample is being immersed within a first liquid 110 residing within the device. Accordingly, due to simplicity consideration, the phrase “in the carrier” is mostly used, though the reader may consider that in some cases, when applicable, the sample may also be placed “on the carrier”, and therefore the phrase “in the carrier” should be understood herein as "in or on the carrier”.
  • the first liquid has a composition as well. Accordingly, subsequent to placing the sample in the carrier, the composition of the first liquid is modified, thus affecting a composition of inter-cellular and/or extra-cellular liquids residing within and around the sample. Afterwards, the carrier is removed from the cryopreservation device and is rapidly cooled by inserting it into a cryogenic medium 112, such as liquid nitrogen or liquid nitrogen slush. Accordingly, the carrier is configured to be inserted into a cryogenic medium, such as liquid nitrogen (LN) or LN slush.
  • a cryogenic medium such as liquid nitrogen (LN) or LN slush.
  • initialization comprises placing the biological sample in the carrier, which is already accommodated in the device and immersed in the first liquid.
  • biological sample 104 e.g. an oocyte
  • a laboratory container 114 e.g. a Petri dish
  • carrier 108 which is accommodated in device 106.
  • this example is non- limiting, and in other cases the biological sample may be placed in the carrier before the carrier is accommodated in the device, or while it is being accommodated.
  • carrier 108 may be any applicable carrier, whose form is not limited by the form illustrated in the present figure.
  • FIG 1 is a non-limiting introductory example to the various embodiments of the invention.
  • FIG 2 illustrates a cryopreservation device 202, according to certain embodiments of the invention.
  • device 202 is an example of a cryopreservation device, such as the one generally denoted 106 in FIG 1, and additional or alternative examples may exist.
  • FIGs 1 and 2 illustrate components denoted by common names in both figures. Such components constitute “common components", wherein the common component illustrated in FIG 2 is considered to be a non-limiting example of the corresponding component in FIG 1.
  • common elements may be denoted in both figures by the same reference numerals (e.g. 104 and 110) wherein the common component in FIG 2 may be a similar or a different embodiment of the corresponding component in FIG 1.
  • FIG 2 common components are denoted in FIG 2 by different reference numerals (e.g. 202 and 210) than the numerals used in FIG 1 (106 and 108, respectively), in order to indicate that the component of FIG 2 represent an example characterized by structural and/or functional aspects additional to the corresponding component of FIG 1.
  • Cryopreservation device 202 comprises a chamber 204 configured to contain the first liquid 110. More specifically, the chamber comprises a first container 206 confining a first space 208 configured to contain the first liquid.
  • first liquid refers herein to a liquid contained within the first container, and more specifically within the first space thereof. It is noted that the volume and/or the composition of the first liquid may change over time, as explained below, with reference to the present figure.
  • Chamber 204 is further configured to accommodate a carrier 210, which is an example of the carrier generally denoted 108 in FIG 1.
  • Carrier 210 is configured to hold the biological sample, thereby enabling immersion of the sample in the first liquid. More specifically, chamber 204 is configured to accommodate carrier 210 so that a sample held by the carrier is accordingly immersed in the first liquid.
  • carrier 210 comprises a permeable member 212 at a bottom thereof.
  • carrier 210 is configured to hold the biological sample on the permeable member
  • chamber 204 is configured to accommodate carrier 210 so that the sample residing in the carrier, on permeable member 212 or in proximity thereto, is immersed in the first liquid.
  • Permeable member 212 is configured to enable a thru-flow of the first liquid between sides thereof, while preventing the biological sample from being carried along with the thru-flow.
  • carrier 210 may comprise non- permeable side walls 214.
  • carrier 210 comprises an access opening 216 configured, e.g., to enable placing the biological sample in the carrier and taking it out therefrom via the access opening.
  • the permeable member comprises openings characterized by a diameter larger than the molecules of the first liquid and smaller than the diameter of the biological sample. In some embodiments the permeable member comprises a mesh characterized by appropriate openings.
  • the characteristics of the permeable member may depend on the characteristics of the biological sample.
  • the permeable member may comprise openings characterized by a diameter in the range of approximately 10 to 100 micrometers. These values are non-limiting though, and any value applicable to the case may be in use.
  • the diameter of the openings may be in the range of approximately 1 to 5 micrometers or approximately 0.4 to 10 millimeter, respectively.
  • the biological sample may carry electric charge, hence, in such cases the size, diameter of the opening may be determined not only based on the physical, morphological form, but also based on electrical characteristics of the permeable member. Understanding this it may be further appreciated that the size of the openings of the permeable member is mostly functionally determined unlike morphological determination.
  • carrier 210 is a non-limiting example of a carrier that may be utilized in device 202, and other carriers may also be used.
  • the carrier comprises one or more permeable members at side-walls thereof.
  • carrier for example a capsule, or a holding pipette, or any other carrier suitable for the case may be utilized.
  • the biological sample may be coupled to the carrier.
  • a biological sample for example an ovary tissue slice, may be coupled to the carrier, e.g., by suturing.
  • a biological sample may be coupled to the carrier by a bioadhesive or by other appropriate biocompatible adhesive.
  • the carrier is configured to hold a single sample. In other embodiments, the carrier is configured to hold even two or more samples (i.e., the carrier is configured to hold one or more samples), thus enabling concurrent vitrification of a plurality of sample.
  • the cryopreservation device is configured to accommodate one carrier. In other embodiments, the cryopreservation device is configured to accommodate two or more carriers, thus enabling concurrent vitrification of samples residing in different carriers.
  • One possible outcome of the latter feature is the possibility to reanimate samples residing in different carriers at different times.
  • Another possible outcome is the possibility to vitrify concurrently samples originated from different entities, e.g. oocytes harvested from different sources, while keeping track on the origin of each sample.
  • the cryopreservation device comprises two or more chambers, and each one of these chambers may be configured to accommodate a single carrier per chamber, one or more carriers, two or more carriers, etc.
  • the carrier may be an element designed specifically for use with a device according to the invention, or a commercially available product requiring or not-requiring adaptations for the device.
  • chamber 204 further comprises a carrier-holding element 228 configured to hold the carrier.
  • a carrier-holding element 228 configured to hold the carrier.
  • some aspects of device 202 depend on carrier 210 being accommodated in an appropriate position within chamber 204.
  • chamber 204 is configured to accommodate carrier 210 so that a sample residing in the carrier, on permeable member 212 or in proximity thereto, is immersed in the first liquid.
  • FIG 2A Further examples of aspects depending on the position of the carrier within the chamber are presented below, for example with reference to FIG 2A, where guiding a flow of liquid towards the carrier depends on a special position of the carrier relative to a flow-guiding element. Accordingly, in some embodiment where an aspect of device 202 depends on an appropriate position of the carrier within the chamber, it should be understood that the carrier-holding element is configured to hold the carrier at the appropriate position.
  • carrier-holding element 228 comprises a carrier-holding ring 230 configured to hold the carrier which rests surrounded by the ring.
  • this example is non-limiting, and any other embodiment appropriate for the case, can be implemented.
  • the structure of the device, or the chamber may allow placing the carrier in a certain position.
  • Device 202 further comprises an inlet 218 configured to add a second liquid 220 into the chamber, whereby the second liquid is inserted into the first space where it is merged into the first liquid.
  • Inlet 218 may be coupled to a first source 222 of the second liquid, wherein the first source may be a manual pump, constituting an "injection pump", (such as a syringe or a squeezable container), a container coupled to an active pump (e.g., an electrical or any other form of motorized pump), or any other applicable source configured to yield the second liquid.
  • an injection pump such as a syringe or a squeezable container
  • an active pump e.g., an electrical or any other form of motorized pump
  • the first source may be configured to be controlled by an automatic controlling mechanism, such as computerized controller.
  • inlet 218 is illustrated to comprise an inlet pipe 224 coupled to chamber 204 via a single inlet-opening 226 at a side-wall of the chamber.
  • Inlet pipe 224 is further illustrated to be coupled to first source 222.
  • the details of the example illustrated in FIG 2 are non-limiting, and other embodiments can be implemented, including, for example, embodiments where the inlet-opening is located at an upper wall or a cover of the chamber, or at a bottom thereof; embodiments where the inlet comprises two or more inlet-openings; embodiments where the inlet does not comprise a pipe and the first source is coupled directly to the inlet-opening; embodiments comprising two or more inlets; combinations of the embodiments listed above; or any other suitable embodiment.
  • Cryopreservation device 202 enables a gradual modification of a composition of the first liquid from a first composition into a third composition, by adding the second liquid characterized by a second composition to the first liquid, as described in the following example.
  • a first volume V of the first liquid, of a first composition is inserted into the first container, the carrier is accommodated in the container, and the sample is placed at the carrier.
  • sample 104 is immersed in the first liquid.
  • a second volume V 2 of second liquid 220 characterized by a second composition, is yielded from first source 222.
  • first modification period T
  • first yielding course Y
  • the instantaneous yielding rate may be constant through T , or it may modify during T .
  • the composition of the first liquid, in which the sample is being immersed is gradually modified during the first modification period from the first composition into a third composition at a first modification course C ⁇ , which represents the instantaneous concentration (i.e. relative portion) C ⁇ (t) of the second liquid within the first liquid.
  • order of operations taking place before the first modification period is non-limiting, and other orders of operations may be implemented, for example, placing the sample at the carrier prior to accommodating the carrier within the chamber, or accommodating the carrier in the chamber before inserting the first liquid to the first container, or any other order of operations appropriate for the case.
  • a liquid of the first composition constitutes a "holding solution”
  • a liquid of the third composition constitutes an "equilibrium solution”
  • the second solution is accordingly configured to modify the composition of the first liquid from the first composition into the third composition.
  • holding solution refers to a solution configured to maintain the biological sample in a physiological condition
  • equilibrium solution refers to a solution configured to bring the sample into a "first equilibrium state”.
  • equilibrium state refers herein to a state wherein (a) a portion of the water contained within the sample has been replaced by premating cryoprotectants and (b) the sample is at osmotic equilibrium with the third solution.
  • first equilibrium state refers to an equilibrium state wherein the concentration of the premating cryoprotectants within the first liquid is equal to a first target concentration.
  • the first target concentration is within the range of 2% to 20%.
  • the first target concentration may be about 5% or 15%, respectively.
  • these first target concentration ranges which are brought here by way of example, are non-limiting, and any other values suitable for the case may be implemented.
  • the holding solution comprises phosphate buffer solution, HEPES solution, or culture medium.
  • these compositions are brought by way of example and are therefore non-limiting, and any other suitable composition may be used when appropriate for the case.
  • the equilibrium solution comprises a combination of the holding solution and permeating cryoprotectants, wherein the permeating cryoprotectants may be, for example, DMSO (dimethylsulphoxide), PROH (1,2- propanediol), EG (ethylene glycol), GLY (glycerol), and any other permeating cryoprotectants suitable for the case.
  • the permeating cryoprotectants may be, for example, DMSO (dimethylsulphoxide), PROH (1,2- propanediol), EG (ethylene glycol), GLY (glycerol), and any other permeating cryoprotectants suitable for the case.
  • DMSO dimethylsulphoxide
  • PROH 1,2- propanediol
  • EG ethylene glycol
  • GLY glycol
  • any other suitable composition may be used if applicable.
  • first composition is a holding solution comprising Hepes TALP medium
  • second composition comprises 16% EG and 16% DMSO
  • the ratio between Vi and V 2 is 1: 1. Therefore, in this specific example, the third composition is an equilibrium solution comprising 8% EG and 8% DMSO, and the first target concentration is 16% CPA.
  • the chamber and more specifically the first space, has a liquid capacity that is sufficiently large to enable a gradual modification in accordance for vitrification.
  • an appropriate range which is suitable for the case, should always be applied in order to prevent damaging osmotic stress and long exposure to cytotoxic substances, thus maintaining viability and functionality of the biological sample, such as reproductive functionality in case of a reproductive biological sample.
  • first concentration course C ⁇ is determined by first volume Vi and first yielding rate Y , as can be expressed in the following equation.
  • cryopreservation device 202 is configured to enable gradual modification of the composition of the first liquid from the first composition to the third composition at an adequate modification course, which is adequate for vitrification, i.e. a modification course which prevents exposing the sample to damaging osmotic stress.
  • the first container of the cryopreservation device is characterized by a liquid capacity which enables the adequate modification course, as explained in the following paragraphs. It is noted that higher values of V and V 2 implies better accuracy of first modification course C ⁇ .
  • composition A a general example of composing ingredient B, C, etc., into a composition A is considered, where quantities of the composition and the ingredients are denoted by X A , 3 ⁇ 4, X c , etc. Due to practical limitations, actual values of 3 ⁇ 4, X c , etc. usually differ from their nominal values by disparity quantities A B , A c , etc. It can be appreciated that in this example, the accuracy of composition A is substantially determined by the ratios ⁇ ⁇ /3 ⁇ 4, AJXc, etc. Therefore, high accuracy of composition A may be achieved by reducing the disparity quantities AB, Ac, etc., or by increasing the nominal quantities 3 ⁇ 4, Xc, etc. Since reducing the disparity quantities typically requires higher accuracy of the equipment, increasing the nominal quantities is usually a more convenient option.
  • first container 206 is configured to have a liquid capacity that is sufficiently large to enable adding second volume V 2 of the second liquid to first volume Vi of the first liquid, wherein V ⁇ and V 2 are large enough to enable adequate modification course.
  • first source 222 comprises a manual injection pump, such as a manual syringe, configured to yield the second liquid.
  • the manual injection pump together with the liquid capacity enables the gradual modification of the composition of the first liquid in accordance with the adequate modification course.
  • the liquid capacity is configured to be large enough to enable gradual modification of the composition of first liquid by utilizing a manual pump for yielding the second liquid, wherein the gradual modification is in accordance with the adequate modification course.
  • first container 206 is configured to be characterized by liquid-capacity of at least 1 milliliter, which is the sum of V ⁇ and V 2 . That is, the volume of the first liquid and the volume of the second liquid occupy together at least 1 milliliter.
  • the first container of the cryopreservation device is configured to be characterized by higher liquid-capacity.
  • the liquid capacity is about 1 to about 5 milliliter, which enables concurrent vitrification of a plurality of oocytes or embryos.
  • the liquid capacity is about 5 to about 10 milliliter, thus enabling vitrification of ovarian cortical slices.
  • cryopreservation device refers size characteristics of the carrier accommodated thereby.
  • chamber 204 of cryopreservation device 202 is configured to accommodate carrier 210 characterized by a size adequate for placing a biological sample therewith by manual pipetting.
  • carrier 210 should enable placing the sample therewith and taking it therefrom.
  • Manual pipetting i.e. utilization of a hand operated pipette for transferring of an object residing within a fluid, is a common practice in laboratories. Therefore, embodiments of device 202 characterized by a chamber configured to accommodate a carrier large enough to enable manual pipetting are advantageous, since they simplify handling of the biological sample.
  • the carrier comprises access opening 216, as illustrated in FIG 2.
  • chamber 204 is configured to accommodate carrier 210 comprising access opening characterized by a diameter large enough to enable placing the sample at the carrier by manual pipetting.
  • the diameter of the access opening is greater or equal to substantially 0.2 millimeter.
  • the chamber of the cryopreservation device is configured to be substantially closed during the preparation of the sample for vitrification, wherein term "substantially closed” indicates that the chamber is generally closed, but may comprise some small openings, for examples the opening of the inlet, and openings of a first and/or second drain described below with reference to FIGs 3 and 5.
  • substantially closed indicates that the chamber is generally closed, but may comprise some small openings, for examples the opening of the inlet, and openings of a first and/or second drain described below with reference to FIGs 3 and 5.
  • One of the advantages of closing the chamber is, for example, protection of the sample from potential contamination.
  • Another advantage for example, is better thermal isolation of the first liquid from the environment.
  • the chamber comprises a cover which is configured to be opened in order to enable inserting the carrier and the sample into the chamber, and taking it thereout, and to be closed during the preparation of the sample.
  • the cryopreservation device is configured to enable modification of the composition of the first liquid from a first composition into a third composition by adding a second liquid into the first liquid.
  • some embodiments of the cryopreservation device comprise elements configured to improve the mixing of the liquids.
  • some embodiments comprise elements configured to guide the second liquid to the carrier, thus enabling better mixing at the vicinity of the biological sample, i.e., in a volume affecting the biological sample, as illustrated in the next figure.
  • FIG 2A illustrates a cryopreservation device 2A02 comprising a flow guiding element 2A06, according to certain embodiments of the invention.
  • device 2A02 is an example of the cryopreservation device, such as the one generally denoted 202 in FIG 2, and additional or alternative examples may exist.
  • FIGs 2 and 2A illustrate common components, wherein the common component illustrated in FIG 2A is considered to be a non-limiting example of the corresponding component in FIG 2.
  • common elements may be denoted in both figures by the same reference numerals (e.g. 218 and 222) wherein the common component in FIG 2A may be a similar or a different embodiment of the corresponding component in FIG 2.
  • FIG 2A common components are denoted in FIG 2A by different reference numerals (e.g. 2A04 and 2A08) than the numerals used in FIG 2 (210 and 214, respectively), in order to indicate that the component of FIG 2 represents an example characterized by structural and/or functional aspects additional to the corresponding component of FIG 2.
  • Device 2A02 comprises flow guiding element 2A06 configured to guide flow of second liquid 220 coming from inlet 218 toward carrier 2A04. Consequently, the flow guiding element thus enables better merging of liquids at the vicinity of sample 104, which resides at carrier 2A04.
  • the carrier comprises non-permeable side-walls 2A08, and a carrier opening 2A10 at an upper part of the carrier.
  • flow guiding element 2A06 may be configured to guide the flow of the second liquid to opening 2A10, as illustrated in the figure.
  • flow guiding element 2A06 may comprise, for example, a channel configured to guide liquid from inlet-opening 226 toward chamber 2A04, as illustrated in the figure.
  • this example is non-limiting, and other flow guiding elements, for example a guiding element comprising a pipe, or any other appropriate guiding element, may be implemented.
  • the cryopreservation device is configured to accommodate a plurality (i.e. two or more) of carriers.
  • the liquid guiding element may be configured to distribute the second liquid coming from the first inlet to the plurality of carriers substantially equally.
  • the flow guiding element may comprise, for example, plurality of channels, as illustrated in the figure.
  • this example is non-limiting, and other flow guiding elements, for example a guiding element comprising a plurality of pipes, sprinklers, or any other appropriate guiding element, may be implemented
  • some embodiments may, additionally or alternatively, comprise other elements for the improvement of the mixing of the liquids.
  • some embodiments may comprise a stirring element, such a magnetic stirrer, or a sprinkler configured to generate flow, or any other element suitable for the case.
  • FIG 3 illustrates a cryopreservation device 302, further comprising a first drain 306, according to certain embodiments of the invention.
  • device 302 is an example of the cryopreservation device, such as the one generally denoted 202 in FIG 2, and additional or alternative examples may exist.
  • FIGs 2 and 3 illustrate common components denoted by common names in both figures, wherein the common component illustrated in FIG 3 is considered to be a non-limiting example of the corresponding component in FIG 2.
  • common elements may be denoted in both figures by the same reference numerals (e.g.
  • FIG 3 may be a similar or a different embodiment of the corresponding component in FIG 2.
  • common components are denoted in FIG 3 by different reference numerals (e.g. 304 and 312) than the numerals used in FIG 2 (204 and 206, respectively), in order to indicate that the component of FIG 3 represents an example characterized by structural and/or functional aspects additional to the corresponding component of FIG 2.
  • systems 2A02 (of FIG 2A) and 302 (of FIG 3) are both examples of system 202 (of Fig 2), it is noted that further examples may comprise structural and/or functional aspects from both FIG 2A and 3.
  • some embodiments may comprise a flow guiding element and a first drain resembling corresponding components illustrated in FIGs 2A and 3, respectively. This example is non-limiting, though, and any other combinations of components, which are appropriate for the case, may be implemented.
  • the first chamber is denoted
  • Device 302 further comprises first drain 306, which is coupled to first space 208 and is configured to drain first liquid 110 therefrom.
  • chamber 304 and first drain 306 are configured together to induce, by draining part of the first liquid, a directional flow of first liquid 110 through permeable member 212; and the directional produces a dragging force which forces biological sample 104 to reside at predetermined location, i.e. substantially adjacent to the permeable member, as explained below.
  • Flow of liquid is illustrated in FIG 3 by arrows.
  • the term "density” refers to the specific gravity of a given object, i.e. to a mass of the object divided a volume thereof. It should be appreciated that when an object A is immersed in a fluid B, wherein object A and fluid B are characterized by densities D 0 bj ect and Dfl ui d, respectively, a position of object A relative to fluid B depends on the relation between the two densities D 0 bj ect and which determines the relationship between a buoyance of the object and a weight thereof.
  • the first composition is characterized by a first density which is lower than an initial density of the biological sample (i.e. prior to the preparation of the sample for vitrification).
  • the second composition is characterized by a second density which is higher than the initial density of the sample. Therefore, during the first period the first liquid is typically characterized by a gradually increasing density.
  • the density of the first liquid might become equal or higher than the density of the sample, thereby causing the sample to float in the first liquid or to rise to an upper surface thereof. Accordingly, in some cases, the sample might reach an opening of the carrier and drift out of the carrier and be lost in the first container. In other cases, the sample might rise to the upper surface of the liquid and adhere to a wall of the carrier. In such cases it might be subsequently very difficult to find the sample and/or it might be damaged as well. Furthermore, in some cases the effectiveness of subsequent stages of the vitrification protocol might be deteriorated when the sample does not reside on the permeable member, as explained in the following examples.
  • a volume of a residual liquid which surrounds the biological sample is reduced prior to inserting the sample into the cryogenic media, as explained below with reference to FIG 4.
  • the reduction of the residual liquid may be performed by aspiration of gas, as described below with reference to FIG 4. In those cases, the reduction of the residual liquid's volume might be less effective when the sample does not reside on the permeable member.
  • the reduction of the residual liquid may be performed by placing the carrier on an element configured to suck liquids, for example an absorbing tissue. In those cases, also, the reduction of the residual liquid's volume might be less effective when the sample does not reside on the permeable member.
  • chamber 304 and first drain 306 are configured so that when part of first liquid 110 is drained by the first drain, a directive flow of liquid through permeable member 212 is consequently being induced. This induced flow produces a dragging force on sample 104, thereby forcing it to reside substantially adjacent to the permeable member 212. Flow of liquid is illustrated in FIG 3 by arrows. It should be noted that the sample is subject to two forces, an elevation force determined by the difference between the buoyancy and weight of the sample, and the dragging force produced determined by the induced directional flow.
  • a position of the sample within the first liquid may also change over time.
  • the sample will not be drifted out of the carrier, and will not adhere to the wall of the carrier, and will eventually reside at the permeable member. Accordingly, as long as the sample remains below the upper level of the first liquid, and does not reach a level of an opening of the carrier, the sample is considered to reside substantially adjacent to the permeable member.
  • the first drain is configured to drain the first liquid out of the chamber.
  • the first drain may comprise an element, e.g. a pump, configured to transfer part of the first liquid from a first location to a second location within the chamber.
  • the first drain may be configured to drain liquid from a first location lower than the permeable member, to a second location higher than the permeable member.
  • first drain 306 comprises a first drain opening 308 in the first container.
  • first drain 306 is coupleable to an aspiration device 310 configured to aspire the first liquid.
  • the aspiration device comprises an aspiration pump, for example a syringe, as illustrated in FIG 3.
  • the details illustrated in FIG 3 are non-limiting, and other embodiments can also be implemented.
  • the first drain may comprise a proximal opening coupled to the first space and a distal opening that is located lower than the proximal opening, thereby enabling passive drainage of the first liquid by gravitation.
  • first drain 306 is configured to enable minor drainage, i.e. drainage of a small portion of the first liquid configured to enable flow through the permeable member. It may be considered that in some cases, e.g., wherein the sample is a piece of tissue whose size is large enough (for example, above 0.25 millimeter in radius), or when the sample is a bulk of cells comprising, for example, at least 0.5 milliliter of cells (net volume), or a cell suspension having a net volume of 0.5 milliliter, it is less important to maintain the sample residing substantially adjacent to the permeable member and hence, in such cases, minor drainage may be skipped.
  • minor drainage i.e. drainage of a small portion of the first liquid configured to enable flow through the permeable member.
  • the first drain is configured to enable "major drainage", which may even exhaust substantially all of the first liquid from the first container.
  • major drainage may even exhaust substantially all of the first liquid from the first container.
  • device 302 may comprises two first drains 306, one configured for minor drainage and the other configured for major drainage. In other embodiments, device 302 may comprise first drain 306 configured for both minor and major drainage. Likewise, in some embodiments, two aspiration devices may be coupled to the first drain, one for minor and the other for major drainage, and in some embodiments the same aspiration device may be used for both minor and major drainage.
  • Major drainage capability may be utilized for abrupt modification of the composition of the first liquid.
  • the composition of first liquid is abruptly modified from the third composition into a fourth composition.
  • the fourth composition is a final-vitrification-solution configured to surround and protect the sample, and to prevent formation of extra-cellular ice crystals.
  • the final-vitrification solution is further configured for partially dehydrating the sample. It is noted that the modification of the composition from the third into the fourth solution is abrupt (e.g. no longer than 60 seconds), in order to avoid overloading the sample with further permeable cryoprotectants, exposing it to damaging osmotic stress.
  • the vitrification solution comprises 15% DMSO (dimethyl sulfoxide), 15% ethandiol, 0.5 moVliter sucrose, 10% serum in medium or 16% DMSO, 16% propanediol, 0.5 mol/liter trehalose, and 10% HAS (human serum albumin) in PBS (phosphate buffered saline).
  • the final-vitrification-solution may further comprise some non-permeating additives, for example sucrose or trehalose, or any other non-permeating additive suitable for the case.
  • those compositions are brought by way of example, and are therefore non-limiting, and any other combination of the above ingredients, or any other composition appropriate for the case, may be utilized.
  • abrupt modification of the composition of the first liquid is enabled by inserting liquids to the first container through the inlet and exhausting liquids thereof through the first drain.
  • abrupt modification may be performed by exhausting the first liquid from the first container, followed by inserting liquids. Inserting and exhausting can be performed either concurrently or sequentially. It should be appreciated that any sequence of insertion and exhaustion operations may be implemented, as appropriate for the case.
  • major drainage is utilized for reducing a volume of a "residual liquid" which surrounds the biological sample, as explained in the following paragraph.
  • residual liquid residual liquid
  • the carrier holding the sample is taken out of the cryopreservation device and is inserted into the cryogenic medium. It should be further recalled that according to some vitrification protocols, the carrier is immersed in liquid residing within the cryopreservation device. Consequently, when the carrier is taken out of the device, the sample may reside within a residual volume of liquid, referred herein as the volume of the residual liquid. As demonstrated in Arav 1992, reduction of volume of the residual liquid is advantageous for vitrification, since the probability of successful vitrification is inversely proportional to the residual liquid's volume.
  • chamber 304 and first drainage 306 are configured so that when the first liquid is drained out of the first container via the first drain, the volume of the residual liquid is reduced. Accordingly, device 302 is configured to reduce the volume of the residual liquid by draining substantially all the first liquid out of the first container via the first drain.
  • inlet 218 is further configured to enable flow of gas into the chamber.
  • device 302 comprises two inlets 218, one configured to deliver liquids and the other configured to enable flow of gas.
  • the same inlet 218 is configured for both.
  • inlet 218 when coupled to the first source 212 the inlet delivers liquids, and when detached from the first source, the same inlet enables flow of gas.
  • inlet 218 may be coupleable to two first sources 212, one configurable to yield first liquid 220 and the other configured to yield gas.
  • first source 212 that is configured to yield gas may be a gas yielding pump, for example a syringe containing gas.
  • inlet 218 may be coupleable to first source 212 which is configured to yield liquid at some stages and to yield gas at other stages. It should be recalled that in some embodiments, device 302 is configured to enable major drainage of the first liquid from the first container. In some embodiments, inlet 218 is configured to enable the major drainage by allowing gas to enter into the first container and replace the first liquid being drained out. It should be noted that without entrance of gas into the chamber, drainage of liquids from the chamber might produce a low pressure therein, thus hampering further drainage and possibly damaging the sample.
  • first drain 306 is further configured to enable aspiration of gas therethrough from the chamber.
  • device 302 comprises two first drains 306, one configured to drain liquid and the other configured to aspirate gas.
  • a single first drain is configured for both.
  • first drain 306 is coupleable to aspirating device 310.
  • first drain 306 which is configured to drain liquid is coupleable to aspiration device 310 configured to aspirate liquids.
  • first drain 306 which is configured to aspirate gas is coupleable to aspiration device 310 configured to aspirate gas.
  • the same aspiration device 310 is configured to aspirate both liquid and gas.
  • device 302 is configured to reduce the volume of the residual liquid by draining the first liquid out of the first container. It should also be recalled that reducing the volume of the residual liquid result in higher cooling rate, which improves the likelihood of successful vitrification with no formation, or with minimal formation, of harmful ice crystals. In some embodiments, device 302 is configured to enable further reduction of the volume of the residual liquid, after the drainage of the first liquid from the chamber. The further reduction is achieved by aspiration of gas from the drained chamber, as explained with reference to the next figure.
  • FIG 4 illustrates a cryopreservation device configured to enable reduction of volume of a residual liquid by aspirating gas, according to certain embodiments of the invention.
  • gas is aspired from a chamber 404 through a first drain 408.
  • device 402 is an example of the cryopreservation device, such as the one generally denoted 302 in FIG 3, and additional or alternative examples may exist.
  • FIGs 3 and 4 illustrate components denoted by common names in both figures, wherein the common component illustrated in FIG 4 is considered to be a non-limiting example of the corresponding component in FIG 3.
  • common elements may be denoted in both figures by the same reference numerals (e.g.
  • FIG 4 may be a similar or a different embodiment of the corresponding component in FIG 3.
  • common components are denoted in FIG 4 by different reference numerals (e.g. 404 and 408) than the numerals used in FIG 2 (304 and 308, respectively), in order to indicate that the component of FIG 4 represents an example characterized by structural and/or functional aspects additional to the corresponding component of FIG 3.
  • the chamber, inlet, and first drain are denoted by 404, 406, and 408, 410, respectively.
  • Chamber 404, inlet 406, and first drain 408 are configured so that aspiration of gas via the first drain induces a flow of gas at a vicinity of biological sample 104, thus removing a part of the residual liquid, by causing it to evaporate.
  • the induced gas flow is illustrated in FIG 4 by arrows. It should be noted that gas aspiration, as illustrated in FIG 4, is usually performed when the chamber is substantially free of liquids, for example after major drainage, as described with reference to FIG 3.
  • FIG 5 illustrates a cryopreservation device 502, further comprising a second drain 508, according to certain embodiments of the invention.
  • device 502 is an example of the cryopreservation device, such as the one generally denoted 202 in FIG 2.
  • FIGs 2 and 5 illustrate common components denoted by common names in both figures, wherein the common component illustrated in FIG 5 is considered to be a non-limiting example of the corresponding component in FIG 2.
  • common elements may be denoted in both figures by the same reference numerals (e.g.
  • FIG 5 wherein the common component in FIG 5 may be a similar or a different embodiment of the corresponding component in FIG 2.
  • common components are denoted in FIG 5 by different reference numerals (e.g. 504 and 506) than the numerals used in FIG 2 (204 and 206, respectively), in order to indicate that the component of FIG 5 represents an example characterized by structural and/or functional aspects additional to the corresponding component of FIG 2.
  • systems 2A02, 302, 402, and 502 are all examples of system 202 (of Fig 2), it is noted that further examples may comprise structural and/or functional aspects from FIGs 2A, 3, 4, and 5.
  • some embodiments may comprise a flow guiding element, a first drain, and a second drain resembling the corresponding components illustrated in FIG 2A, 3, and 5, respectively.
  • a flow guiding element for example, a first drain, and a second drain resembling the corresponding components illustrated in FIG 2A, 3, and 5, respectively.
  • the chamber is denoted 504, and the first container is denoted 506.
  • Device 502 further comprises second drain 508, which is configured to enable flow of an excessive volume of the first liquid exceeding a first-level- limit 510 out of the first container, thus constraining a level of the first liquid substantially below the first-liquid-limit.
  • the level of the term “below” is considered in the last sentence to mean “below or equal”. It is further noted that in some cases the level of the first liquid may temporarily exceed the first-liquid-level, due to hydrodynamic effects, while the excessive liquid flows out of the first container. Additionally or alternatively, the level of the first liquid may slightly exceed the first-liquid-level due to a surface tension of the first liquid. Accordingly, “substantially below the first- liquid-limit” is considered herein to mean below or equal, and to further allow for some transient exceeding due to hydrodynamic effects, and for some slight steady- state exceeding due to liquid tension.
  • the second drain may be implemented in various configurations, some of which are brought, by way of example, in FIGs 5, 5A, and 6.
  • FIG 5A illustrates a cryopreservation device 5A02 which enables in-field configuration of the first-liquid- level-limit
  • FIG 6 illustrates two cryopreservation devices 602a and 602b comprising a second container 612.
  • the second drain is configured to enable flow of the excessive volume of the first liquid out of the first chamber.
  • the excessive liquid flows out of the chamber and is collected in an auxiliary container 512.
  • this is non-limiting, and in other embodiments the excessive liquid may still remain within the chamber.
  • the chamber further comprises a second container 612, configured to collect the excessive liquid flowing out of the first container.
  • the second drain comprises a pipe coupled to a space confined by the first container.
  • the second drain comprises a pipe comprising a proximal and distal second- drain-pipe openings, located inside and outside the first container, respectively.
  • second drain 608a comprises a second- drain opening in a container side-wall 614 of the first container.
  • second drain 608b comprises a second- drain opening residing above an upper edge of container side-wall 614.
  • the first-liquid-limit is a fixed predetermined level.
  • first-liquid-limit 610 is determined by the vertical location of the second-drain openings 608a and 608b.
  • the first-liquid-level may be configured at the laboratory as appropriate for the case.
  • the first-liquid- level 5A12 can be varied by varying the vertical level of the second-drain-pipe opening 5A14.
  • the flow of the excessive liquid out of the first container may enable improved merging of the second liquid into the first liquid.
  • the cryopreservation device comprises flow guiding element 2A06 configured to guide flow of second liquid 220 coming from inlet 218 toward carrier 2A04, in order to improve merging of liquids at the vicinity of sample 104, which resides at carrier 2A04.
  • FIG 7 illustrates a cryopreservation device 702 configured to improve merging of liquids by utilizing flow of excessive liquid, according to certain embodiments of the invention.
  • device 702 is an example of the cryopreservation device, such as the one generally denoted 202 in FIG 2.
  • FIGs 2 and 7 illustrate common components denoted by common names in both figures, wherein the common component illustrated in FIG 7 is considered to be a non-limiting example of the corresponding component in FIG 2.
  • common elements may be denoted in both figures by the same reference numerals (e.g. 218 and 222) wherein the common component in FIG 7 may be a similar or a different embodiment of the corresponding component in FIG 2.
  • FIG 7 common components are denoted in FIG 7 by different reference numerals (e.g. 704 and 706) than the numerals used in FIG 2 (204 and 206, respectively), in order to indicate that the component of FIG 7 represents an example characterized by structural and/or functional aspects additional to the corresponding component of FIG 2.
  • systems 2A02, 302, 402, 502, 5A02, 602a, and 602b are all examples of system 202 (of Fig 2), it is noted that further examples may comprise structural and/or functional aspects from FIGs 2A, 3, 4, 5, 5A, and 6.
  • some embodiments may comprise a flow guiding element, a first drain, a second drain, and a second container resembling the corresponding components illustrated in FIG 2A, 3, and 5, 5A, and 6, respectively.
  • the chamber is denoted 704, the first container is denoted 706, the flow guiding element is denoted 708, the second drain is denoted 710, the first-level- limit is denoted 712, and the carrier is denoted 714.
  • the carrier comprises non-permeable walls 716, a permeable member 718, and a carrier opening 718.
  • non-permeable walls 716 are side-walls, permeable member 718 is located at a bottom of the carrier, and carrier opening 718 is located at an upper part thereof.
  • this example is non- limiting, and in other carriers the carrier may be configured with the walls, the permeable member, and the carrier opening, located at other relative positions.
  • chamber 704 is configured to accommodate carrier 714 so that permeable member 718 and carrier opening 718 reside below and above first-level-limit 712, respectively.
  • flow guiding element 708 is configured to guide second liquid 220 to flow into carrier opening 718.
  • the arrangement described above results in a flow of the second liquid into the carrier, where it is merged with the first liquid residing therein, and a flow of the first liquid out of the carrier, via permeable member 718, thus enabling further flow of second liquid into the carrier. Consequently, this arrangement enables improved merging of the second liquid into the first liquids at the vicinity of sample 104, which resides at the carrier.
  • the flow of the liquids is illustrated in the figure by arrows.
  • FIG 8 illustrates a cryopreservation device 802 configured to enable visual inspection of the biological sample residing within the chamber, according to certain embodiments of the invention.
  • device 802 is an example of the cryopreservation device, such as the one generally denoted 202 in FIG 2.
  • FIGs 2 and 8 illustrate common components denoted by common names in both figures, wherein the common component illustrated in FIG 8 is considered to be a non-limiting example of the corresponding component in FIG 2.
  • common elements may be denoted in both figures by the same reference numerals (e.g. 212 and 222) wherein the common component in FIG 8 may be a similar or a different embodiment of the corresponding component in FIG 2.
  • FIG 8 common components are denoted in FIG 8 by different reference numerals (e.g. 804 and 806) than the numerals used in FIG 2 (204 and 206, respectively), in order to indicate that the component of FIG 8 represents an example characterized by structural and/or functional aspects additional to the corresponding component of FIG 2.
  • systems 2A02, 302, 402, 502, 5A02, 602 (a and b), and 702 are all examples of system 202 (of Fig 2)
  • further examples may comprise structural and/or functional aspects from FIGs 2A, 3, 4, 5, 5A, 6, and 7.
  • some embodiments may comprise a flow guiding element, a first drain, a second drain, and a second container resembling the corresponding components illustrated in FIG 2A, 3, and 5, 5A, and 6, respectively.
  • the chamber is denoted 804, and the first container is denoted 806.
  • the chamber of the cryopreservation device may be constructed of transparent materials, whereby enabling visual inspection of its content. However, in many other cases the chamber is non-transparent. Therefore, in some embodiments, which are illustrated in FIG 8, cryopreservation device 802 is configured to enable visual inspection of the biological sample according to embodiments described in the following examples, or a combination thereof, or any other embodiments appropriate for the case.
  • the chamber of the cryopreservation device comprises an inspection element configure to enable visual inspection of the sample.
  • the inspection element may be an internal inspection element residing inside the chamber. In some embodiments the internal inspection element comprises a CCD camera.
  • the inspection element comprises an inspection window 808, which constitutes an opening in a boundary (e.g. side-wall, cover, floor, etc.) of the chamber, wherein the inspection window enables inspecting the sample therethrough.
  • the chamber of the cryopreservation device comprises an illumination element configure to enable illuminating of sample 104 while inspecting thereof.
  • the illumination element may be an internal illumination element residing inside the chamber.
  • the internal inspection element is a LED (liquid emitting diode).
  • this example is non- limiting, and other internal illumination elements, for example an optic fiber, or any other illumination element suitable for the case, may be utilized.
  • the illumination element comprises an illumination window 810, which constitutes an opening in a boundary of the chamber, wherein the illumination window enables illuminating the sample by light penetration thereby.
  • the chamber is configured to accommodate the carrier so that the sample resides substantially between the illumination element and the inspection element, thus enabling trans- illumination of the sample, i.e. illuminating the inspected sample by light passing therethrough. It is noted that since oocytes and embryos are substantially transparent, trans-illumination is more convenient for visual inspection thereof than reflected illumination.
  • chamber 804 is configured to accommodate carrier 220 so that sample 104 resides substantially between illumination window 810 and inspection window 808, thus enabling transillumination of the sample.
  • trans-illumination is enabled by locating illumination window 808 substantially below carrier 220, e.g. at a bottom of first container 806, and locating inspection window 810 substantially above the carrier, e.g. at a cover of chamber 804.
  • the embodiment illustrated in the figure is non-limiting, and other embodiments may be implemented, for example embodiment wherein trans-illumination is further enable by a reflective surface (e.g. a mirror) located within the carrier, or embodiments which enable reflected-illumination rather than trans-illumination, or any other embodiment appropriate for the case.
  • the inspection window and/or the illumination window are configured to be closed by an inspection-window-cover and or by an illumination- window-cover comprising a transparent member, thus enabling visual inspection while maintaining the chamber closed.
  • chamber 804 further comprises one or more fastening mechanisms configured to fasten the inspection- window-cover and or the illumination-window-cover to the boundary of the chamber, thus securing the closure of the chamber.
  • Fastening mechanism may be implemented in according to various methods known in the art, including for example, seal supported threading or any other method appropriated for the case.
  • the one or more window covers may be disposable elements. In other embodiments the one or more window covers may be elements configured to be sterilized. In some embodiments, the one or more window covers may be Petri dishes, which enable convenient cleaning and sterilization of the device.
  • the inspection window comprises one or more optical lenses.
  • cryopreservation device to enable visual inspection of the biological samples residing therein enable better control on the preparation of the biological sample for vitrification, thereby resulting in higher probability for successful vitrification.
  • One example for the benefit of the visual inspection is related to the minor drainage of the first liquid. As explained with reference to FIG 3, in some embodiments a minor part of the first liquid is drained through the first drain, in order to force the biological sample to reside substantially adjacent to the permeable member. Visual inspection enables preforming the minor drainage responsive to the distance of the sample from the permeable member, thus maintaining a desired location of the sample at minimal drainage.
  • the visual inspection is related to the gradual modification of the composition of the first liquid.
  • successful vitrification depends on the modification course of the first liquid, which is determined by the first yielding course of the second liquid.
  • Visual inspection enables controlling the first yielding course responsive to information obtained during visual indication about a status of the sample.
  • the first yielding course may be controlled responsive to changes in a volume of the sample.
  • an excessive reduction of the volume of the sample indicates an excessive osmotic stress, and is therefore responded by a reduction of the yielding rate.
  • the first yielding course may be controlled responsive to changes in a position of the sample.
  • the yielding course should not be reduced below a minimal level, in order not to increase toxicity by excessive exposure to the vitrification solution.
  • FIG 9 schematically illustrates a cryopreservation method 902 for vitrification of a reproductive multi cell suspension, by using a cryopreservation device in accordance with embodiments of the invention.
  • the multi cell suspension (cells that are in suspension) may comprise an oocyte, an embryo, sperm, or another reproductive multi-cell suspension.
  • the cryopreservation method comprises initialization 904, gradual modification 906, abrupt modification 908, and rapid cooling 912.
  • method 902 may also comprise residual liquid reduction.
  • Initialization comprises immersing the multi cell suspension in a first liquid residing in a chamber of the device.
  • the multi-cell suspension is associated with a carrier, and the carrier is accommodated within the chamber, thereby immersing the multi-cell suspension in the first liquid.
  • Volume and composition of the first liquid during the initialization are referred to as the first volume and the first composition, respectively.
  • the initialization was described, in depth, with reference to FIGs 1 and 2.
  • Gradual modification comprises modifying the first liquid from the first composition to a third composition by adding a second liquid thereto. Composition and volume of the second liquid are referred to as the second composition and the second volume, respectively.
  • Gradual modification is performed at a first modification course, which is adequate for vitrification. The gradual modification was described, in depth, with reference to the previous figures, and mainly with reference to FIG 2.
  • Abrupt modification comprises modifying the first liquid from the third composition to a forth composition. Abrupt modification is performed by draining substantially all the first liquid, and adding a third liquid into the chamber through the inlet. A composition of the third liquid is referred to as the forth composition. Abrupt modification was described, in depth, with reference to the previous figures, and mainly with reference to FIG 3.
  • the rapid cooling comprises taking the carrier, which the multi-cell suspension associated with it, out of the chamber, and inserting the carrier into a cryogenic medium.
  • the rapid cooling was described, in depth, with reference to the previous figures, and mainly with reference to FIG 1.
  • adding liquid for gradual modification and/or for abrupt modification is performed manually, e.g. by a manual injection pump, such as a syringe.
  • a manual injection pump such as a syringe.
  • the utilization of a manual injection pump was described, in depth, with reference to the previous figures, and mainly with reference to FIG 2.
  • minor and/or draining of liquids is performed manually, e.g. by a manual aspiration pump, such as a syringe.
  • a manual aspiration pump such as a syringe.
  • the utilization of a manual aspiration pump was described, in depth, with reference to the previous figures, and mainly with reference to FIG 3.
  • the vitrification method further comprises maintaining the multi cell suspension substantially adjacent to a permeable member of the carrier. Maintaining adjacent to a permeable member is performed by draining part of the first liquid, which is referred to as minor drainage.
  • the minor drainage induces a directional flow of the first liquid through the permeable member, and the directional flow applies a dragging force on the multi-cell suspension, thereby forcing the multi- cell suspension to reside substantially adjacent to the permeable member.
  • minor drainage is performed during the gradual modifying. However, this is non-limiting, and minor drainage may be performed, additionally or alternatively, at other times too.
  • the minor drainage and its utilization for maintaining the multi cell suspension substantially adjacent to the permeable member were described, in depth, with reference to the previous figures, and mainly with reference to FIG 3.
  • associating the multi cell suspension with the carrier is performed by manual pipetting, for example by placing the multi cell suspension in the carrier by manual pipetting. Utilization of a manual pipette was described, in depth, with reference to the previous figures, and mainly with reference to FIG 2.
  • the sum of the first volume and the second volume is at least 1 milliliter. In other embodiments, the sum of the first volume and the second volume is at least 5 milliliter.
  • the volumes of the first and the second liquids are described, in depth, with reference to the previous figures, and mainly with reference to FIG 2.
  • the chamber is configured to accommodate two or more carriers.
  • the method comprises concurrent vitrification of multi-cell suspensions associated with a plurality of carriers.
  • two or more multi cell suspensions, which association with two or more carriers, are immersed concurrently immersed in the first liquid residing in the chamber, and concurrently prepared for vitrification.
  • Concurrent vitrification is described, in depth, with reference to the previous figures, and mainly with reference to FIGs 2 and 2A.
  • the method further comprises constraining a level of the first liquid substantially below a first-liquid-limit. Constraining is performed by enabling out-flow of an excessive volume of the first liquid, wherein the term "excessive volume" refers to a volume of the first liquid which exceeds the first level limit. In some embodiments, the excessive volume flows out of the chamber. In other embodiments, the excessive volume flows out of a first container of the chamber, and is collected in a second container. Constraining a level of the first liquid is described, in depth, with reference to the previous figures, and mainly with reference to FIGs 5, 5A, and 6.
  • the vitrification method further comprises visual inspection of the multi-cell suspension residing within the chamber.
  • visual inspection comprises trans-illumination of the multi-cell suspension. Visual inspection is described, in depth, with reference to the previous figures, and mainly with reference to FIG 8.
  • visual inspection is utilized for controlling the preparation of the multi-cells for vitrification.
  • adding the second liquid is controlled responsive to information obtained during visual inspection of the multi-cell suspension.
  • a yielding rate, at which the second liquid may be added to the first liquid may be controlled responsive to visual indications of a status of the multi-cell suspension, thereby resulting in an adequate modification course.
  • the minor drain is controlled respective to information obtained during the visual inspection, thus enabling maintaining the multi cell suspension substantially adjacent to a permeable member of the carrier.
  • the vitrification method further comprises a residual liquid reducing, wherein a volume of a residual liquid surrounding the multi-cell suspension is reduced.
  • residual liquid reducing is performed by draining substantially all the first liquid and aspiring gas. The aspiration induces a flow of gas at a vicinity of the multi-cell suspension, thereby removing a part of the residual liquid. Gas aspiration and its utilization for reducing the volume of the residual liquid is inspection is described, in depth, with reference to the previous figures, and mainly with reference to FIG 4.
  • cryopreservation device and the method of utilization thereof, in accordance with embodiments of the invention, have been examined in experiments, some examples thereof presented in Appendices A and B.
  • VS vitrification solution: 16% ethylene glycol (EG)
  • Procedure 1 Add 5.5 ml HEPES-TALP into a device, e.g., a device described in the
  • VS vitrification solution: 20% ethylene glycol (EG)
  • Disposable sterile scalpel blades (size 20 or 21)
  • Petri dish (100x20 mm)
  • EXPERIMENT 1 Effect on oocyte maturation
  • COCs were divided into 3 groups:
  • EXPERIMENT 3 Effect on oocyte developmental competence, fertilization and cleavage
  • COCs were divided into 3 groups:
  • Example of an experiment on human ovarian slices Vitrified ovaries were donated in this experiment. The ovaries were warmed in the conventional warming procedure and histological evaluation was done by microscopy.
  • the ovaries were then placed in the device and processed according to the following protocol:
  • VS vitrification solution: 20% ethylene glycol (EG)
  • Disposable sterile scalpel blades (size 20 or 21)
  • Petri dish (100x20 mm)
  • Petri dish (100x20 mm)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La présente invention concerne un dispositif de préparation d'un échantillon biologique pour la vitrification, et un procédé d'utilisation de celui-ci. Le dispositif comprend une chambre, une entrée, et une première évacuation. La chambre est configurée pour contenir un premier liquide et pour accueillir un support permettant de maintenir l'échantillon immergé dans le premier liquide. L'entrée est configurée pour ajouter un deuxième liquide dans la chambre afin de modifier une composition du premier liquide. La première évacuation est configurée pour drainer le premier liquide de la chambre. La chambre a une capacité de liquide qui est suffisamment grande pour permettre une modification progressive de la composition en fonction d'une progression de modification adéquate pour préparer l'échantillon pour la vitrification.
PCT/IL2015/050691 2014-07-03 2015-07-03 Dispositif pour la préparation d'un échantillon biologique pour vitrification, et procédé d'utilisation de celui-ci Ceased WO2016001933A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ILPCT/IL2014/050605 2014-07-03
IL2014050605 2014-07-03

Publications (1)

Publication Number Publication Date
WO2016001933A1 true WO2016001933A1 (fr) 2016-01-07

Family

ID=55018544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2015/050691 Ceased WO2016001933A1 (fr) 2014-07-03 2015-07-03 Dispositif pour la préparation d'un échantillon biologique pour vitrification, et procédé d'utilisation de celui-ci

Country Status (1)

Country Link
WO (1) WO2016001933A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018195496A1 (fr) * 2017-04-21 2018-10-25 Irvine Scientific Sales Company, Inc. Dispositif de vitrification et procédé de préparation d'échantillon
US11856947B2 (en) 2020-02-17 2024-01-02 Cook Medical Technologies Llc System for automated permeation of a biological material and method of using same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297600A1 (en) * 2009-05-19 2010-11-25 Genx International, Inc. Flooding dish and method for changing media in the dish in the preparation of mammalian specimen culture and for cryo-preservation, freezing, vitrification and the thawing and warming of such specimens
US20100317108A1 (en) * 2008-02-25 2010-12-16 Sydney Ivf Limited Cryopreservation of Biological Cells and Tissues
US20110207112A1 (en) * 2008-07-23 2011-08-25 Mariposa Biotechnology, Inc Automated system for cryopreservation of oocytes, embryos, or blastocysts

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317108A1 (en) * 2008-02-25 2010-12-16 Sydney Ivf Limited Cryopreservation of Biological Cells and Tissues
US20110207112A1 (en) * 2008-07-23 2011-08-25 Mariposa Biotechnology, Inc Automated system for cryopreservation of oocytes, embryos, or blastocysts
US20100297600A1 (en) * 2009-05-19 2010-11-25 Genx International, Inc. Flooding dish and method for changing media in the dish in the preparation of mammalian specimen culture and for cryo-preservation, freezing, vitrification and the thawing and warming of such specimens

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018195496A1 (fr) * 2017-04-21 2018-10-25 Irvine Scientific Sales Company, Inc. Dispositif de vitrification et procédé de préparation d'échantillon
JP2023123549A (ja) * 2017-04-21 2023-09-05 フジフイルム アーバイン サイエンティフィック， インコーポレイテッド サンプルを調製するためのガラス化デバイス及び方法
EP4233542A3 (fr) * 2017-04-21 2023-11-22 FUJIFILM Irvine Scientific, Inc. Dispositif de vitrification et procédé de préparation d'échantillon
JP7622139B2 (ja) 2017-04-21 2025-01-27 フジフイルム アーバイン サイエンティフィック， インコーポレイテッド サンプルを調製するためのガラス化デバイス及び方法
US11856947B2 (en) 2020-02-17 2024-01-02 Cook Medical Technologies Llc System for automated permeation of a biological material and method of using same

Similar Documents

Publication Publication Date Title
Tríbulo et al. Production and culture of the bovine embryo
CA2808101C (fr) Methode de vitrification superficielle a l'azote liquide
US11998003B2 (en) Devices and methods for preparation of a biological sample for a cryoprocedure
US20150313211A1 (en) A Method of Vitrification
Santos et al. Preservation of caprine preantral follicle viability after cryopreservation in sucrose and ethylene glycol
WO2017122210A1 (fr) Dispositifs automatiques conçus pour mettre en œuvre un protocole cryogénique sur au moins un échantillon biologique porté par un ou plusieurs supports
Somfai et al. Vitrification of porcine oocytes and zygotes in microdrops on a solid metal surface or liquid nitrogen
Huebinger et al. Reversible cryopreservation of living cells using an electron microscopy cryo-fixation method
WO2016001933A1 (fr) Dispositif pour la préparation d'un échantillon biologique pour vitrification, et procédé d'utilisation de celui-ci
Saragusty Directional freezing for large volume cryopreservation
Kasai Cryopreservation of mammalian embryos: vitrification
Fay et al. Determination of metabolic stability using cryopreserved hepatocytes from rainbow trout (Oncorhynchus mykiss)
EP1131998A1 (fr) Procédé de cryoconservation de cellules
DK2611290T3 (en) PROCEDURE FOR CRYOP PRESERVATION OF HUMAN SPERMA TOZOES WITHOUT SEAT PLASMA USING A QUICK AND SIMPLE ASEPTIC VITRIFICATION DEVITRIFICATION PROCESS
WO2018069756A1 (fr) Dispositifs et procédés de réchauffement d'un échantillon biologique cryoconservé
Amorim et al. Cryopreservation of ovine primordial follicles using dimethyl sulfoxide
Gook Chapter 12 human ovarian tissue slow freezing
Dike Efficiency of intracellular cryoprotectants on the cryopreservation of sheep oocytes by controlled slow freezing and vitrification techniques
US11617365B2 (en) Devices and methods for preparation of a biological sample for a cryoprocedure
Huebinger et al. Self‐Pressurized Rapid Freezing as Cryo‐Fixation Method for Electron Microscopy and Cryopreservation of Living Cells
RU141452U1 (ru) Устройство для витрификации ооцитов и эмбрионов млекопитающих
US12472475B2 (en) Methods of supercooling aqueous samples
US20190008142A1 (en) Automatic devices configured to perform a cryoprocedure on at least one biological sample carried by one or more carriers
CN113439739A (zh) 冷冻保存作业辅助治具
JP7423412B2 (ja) 凍結保存用治具の固定具

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15815440

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15815440

Country of ref document: EP

Kind code of ref document: A1